

West Virginia Medicaid Drug Utilization Review Board Minutes

March 8, 2017

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD (via phone)
Michael Lonsinger, Pharm D
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Myra Chiang, MD
Ernest Miller, DO
Kate Forman, PharmD

Members Absent:

Kc Lovin, PA-C, Vice-Chair
John Vanin, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant
Gail Goodnight, RPh, Rebate Coordinator

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Goold Health Systems
Mark Garofoli, PharmD, MBA, Rational Drug Therapy Program (RDTP)
Matthew Waldrop, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

- A.** Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:07 p.m., EDT). The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM NOVEMBER 16, 2016 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

IV. NEW BUSINESS

A. **Speakers**

- 1. None

B. **Updates from the January 25, 2017 Pharmacy & Therapeutics Committee Meeting**

- 1. P&T meeting was cancelled, no updates.

C. **PDL Prior Authorization Criteria (Attachment A)**

- 1. **Zurampic** – A motion to approve criteria as presented was made, seconded, and passed.
- 2. **Onzentra XSAIL** – A motion to approve criteria as presented was made, seconded, and passed.
- 3. **Hepatitis C** – A motion to amend criteria to reduce fibrosis requirements to a confirmed fibrosis level of F2 or greater was made, seconded, and passed.
- 4. **Hyperparathyroid Agents** – A motion to approve criteria as presented was made, seconded, and passed.
- 5. **Adlyxin** – A motion to approve criteria as presented was made, seconded, and passed.
- 6. **Soliqua** – A motion to approve criteria as presented was made, seconded, and passed.
- 7. **PDL policy on non-preferred combination agents** – the Board agreed to the addition of the following statement to the PDL policy, “Unless otherwise indicated, non-preferred combination products require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred single-ingredient agents.”
- 8. **Ophthalmic Antibiotics** – A motion to approve criteria as presented was made, seconded, and passed.
- 9. **Hetlioz** – A motion to approve criteria as presented was made, seconded, and passed.

V. REPORTS

- A. **Molina Quarterly Report – Fourth Quarter 2016** – Eric Sears presented an overview of the Molina 2016 Fourth Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. **Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the Fourth Quarter 2016. Mark Garofoli presented an overview of the Safe and Effective Management of Pain Guidelines (SEMP).
- C. **Health Information Designs** – Matthew Waldrop presented an overview of the Fourth Quarter 2016 retrospective drug utilization activity (Attachment C). The presentation indicated the number of profiles reviewed, letters mailed to

providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. Pat Regan, PharmD, has retired from the DUR Board.
- B. Karen Fitzpatrick, MD, has retired from the DUR Board.

VII. NEXT MEETING AND ADJOURNMENT

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:17 p.m., EDT.
- C. The next meeting will be Wednesday, May 31, 2017 from 4:00 p.m.–6:00 p.m. and located at WVDHR.

Submitted by:

Matthew Waldrop, PharmD, Health Information Designs